Monoclonal antibodies in diabetes: Almost approaching the dream?;Anticorps monoclonaux en diabétologie: Jusqu'au bout du rêve?

Revue Medicale de Liege

Volumn 64, Issue 5-6, 2009, Pages 327-333

  Philips, J C ^a   Keymeulen, B ^b   Mathieu, C ^c   Scheen, A J ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

^c UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Anti CD20 antibodies; Anti CD3 antibodies; Beta cell; Insulin secretion; Islet transplantation; Monoclonal antibodies; Type 1 diabetes

Indexed keywords

BASILIXIMAB; CD20 MONOCLONAL ANTIBODY; INSULIN; INTERLEUKIN 2; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD3; OTELIXIZUMAB; PLACEBO; RITUXIMAB; TEPLIZUMAB; UNCLASSIFIED DRUG;

ANTIGEN PRESENTING CELL; B LYMPHOCYTE; CLINICAL PRACTICE; DRUG MECHANISM; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; NONHUMAN; NONOBESE DIABETIC MOUSE; PANCREAS ISLET; PANCREAS ISLET BETA CELL; PANCREAS ISLET TRANSPLANTATION; REVIEW; T LYMPHOCYTE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; ANTIGENS, CD3; DIABETES MELLITUS, TYPE 1; HUMANS; IMMUNOSUPPRESSIVE AGENTS;

EID: 67749139778     PISSN: 00353663     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (34)

1. Geenen V, Brilot F, Louis C, et al.- Nouvelles données sur la pathogénie du diabète de type 1. Rev Med Liege, 2005, 60, 291-296. (Pubitemid 40941496)
2. Weets, I, De Leeuw I, Du Caju M, et al.- The incidence of type 1 diabetes in the age group 0-39 years has not increased in Antwerp (Belgium) between 1989 and 2000: evidence for earlier disease manifestation. Diabetes Care, 2002, 25, 840-846.
3. Weets I, Truyen I, Philips JC, Gorus F.- Diagnostic précoce et prevention du diabète de type 1 : rôle du Registre Belge du Diabète. Rev Med Liege, 2005, 60, 306-312. (Pubitemid 40941499)
4. Philips JC, Radermecker RP.- L'insulinothérapie dans le diabète de type 1. Rev Med Liege, 2005, 60, 322-328. (Pubitemid 40941502)
5. The Diabetes Control and Complications Trial Research Group.- The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med, 1993, 329, 977-986.
6. Mathieu C, Keymeulen B.- Prévention du diabète de type 1 : essais chez la souris et chez l'homme. Rev Med Liege, 2005, 60, 303-305. (Pubitemid 40941498)
7. Li L, Yi Z, Tisch R, Wang B.- Immunotherapy of type 1 diabetes. Arch Immunol Ther Exp, 2008, 56, 227-236.
8. Keymeulen B.- New therapies aimed at the preservation or restoration of beta cell function in type 1 diabetes. Acta Clin Belg, 2006, 61, 275-285. (Pubitemid 44912918)
9. Cernea S, Pozzilli P.- New potential treatments for protection of pancreatic B-cell function in Type 1 diabetes. Diabet Med, 2008, 25, 1259-1267.
10. Assan R, Feutren G, Sirmai J.- Cyclosporine trials in diabetes : updated results of the French experience. Transplant Proc, 1988, 20, 178-183. (Pubitemid 18158702)
11. Parving HH, Tarnow L, Nielsen FS, et al.- Cyclosporin nephrotoxicity in type 1 diabetic patients. A 7-year follow-up study. Diabetes Care, 1999, 22, 478-483. (Pubitemid 29106908)
12. Chatenoud L.- The use of CD3-specific antibodies in autoimmune diabetes : a step toward the induction of immune tolerance in the clinic. Handb Exp Pharmacol, 2008, 181, 221-236.
13. Bour-Jordan H, Bluestone JA.- B cell depletion : a novel therapy for autoimmune diabetes ? J Clin Invest, 2007, 117, 3642-3645. (Pubitemid 350224070)
14. Chatenoud L, Thervet E, Primo J, et al.- Anti-CD3 antibody induces long-term remission of overt autoim munity in nonobese diabetic mice. Proc Natl Acad Sci USA, 1994, 91, 123-127. (Pubitemid 24018655)
15. Kaufman A, Herold KC.- Anti-CD3 mAbs for treatment of type 1 diabetes. Diabetes Metab Res Rev, 2009, 25, 302-306.
16. Herold KC, Hagopian W, Auger J, et al.- Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med, 2002, 346, 1692-1698. (Pubitemid 34547482)
17. Keymeulen B, Vandemeulebroucke E, Ziegler AG, et al.- Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med, 2005, 352, 2598-2608. (Pubitemid 41007846)
18. Immune Tolerance Network.- Clinical trials for newly diagnosed type 1 diabetes. http://www. newonsetdiabetes.org/trials.html.
19. Liossis S-NC, Sfikakis PP.- Rituximab-induced B cell depletion in autoimmune diseases : potential effects on T cells. Clin Immunol, 2008, 127, 280-285.
20. Bonnet C, Beguin Y, De Prijck B, et al.- Anticorps monoclonaux en hématologie en 2009. Rev Med Liège, 2009, 64, 268-273.
21. Hu C, Rodriguez-Pinto D, Du W et al.- Treatment with CD20-specific antibody prevents and reverses autoimmune diabetes in mice. J Clin Invest, 2007, 117, 3642-3645. (Pubitemid 350224095)
22. De Roover A, Detry O, Coimbra C, et al.- La place de la transplantation pancréatique dans le traitement du diabète. Rev Med Liege, 2005, 60, 350-354. (Pubitemid 40941507)
23. Lee DD, Grossman E, Chong AS.- Cellular therapies for type 1 diabetess. Horm Metab Res, 2008, 40, 147-154.
24. Couri CE, Oliveira MC, Stracieri AB , et al.- C-peptide levels and insulin independance following autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA, 2009, 301, 1573-1579.
25. Nanji S, Shapiro A.- Islet transplantation in patients with diabetes mellitus: choice of immunosuppression. BioDrugs, 2004, 5, 315-328. (Pubitemid 39381948)
26. Bonvoisin C, Weekers L, Grosch S, Krzesinski JM.- Les anticorps monoclonaux en transplantation rénale. Rev Med Liège, 2009, 64, 287-292.
27. Shapiro A, Lakey J, Ryan E et al.- Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med, 2000, 343, 230-238. (Pubitemid 30490390)
28. Shapiro AM, Ricordi C, Hering BJ, et al.- International trial of the Edmonton protocol for islet transplantation. N Engl J Med, 2006, 355, 1318-1330. (Pubitemid 44465460)
29. Gillard P, Ling Z, Mathieu C, et al.- Comparison of sirolimus alone with sirolimus plus tacrolimus in type 1 diabetic recipients of cultured islet cell grafts. Transplantation, 2008, 85, 256-263. (Pubitemid 351156856)
30. Keymeulen B, Gillard P, Mathieu C, et al.- Correlation between beta cell mass and glycemic control in type 1 diabetic recipients of islet cell graft. Proc Natl Acad Sci U S A, 2006, 103, 17444-17449. (Pubitemid 44788988)
31. Ryan E, Paty B, Senior P et al.- Five-year follow-up after clinical islet transplantation. Diabetes, 2005, 54, 2060-2069. (Pubitemid 40911269)
32. Hu C, Deng S, Wong FS, et al.- Anti-CD20 treatment prolongs syngeneic islet graft survival and delays the onset of recurrent autoimmune diabetes. Ann N Y Acad Sci, 2008, 1150, 217-219.
33. Fiorina P, Secchi A.- Pancreatic islet cell transplant for treatment of diabetes. Endocrinol Metab Clin North Am, 2007, 36, 999-1013. (Pubitemid 350026256)
34. Pozzilli P, Leslie RD.- New prospects for immunotherapy at diagnosis of type 1 diabetes. Diabetes Metab Res Rev, 2009, 25, 299-301.